- Home
- JAZZ vs ATR Comparison
JAZZ vs ATR Comparison
Compare JAZZ & ATR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAZZ
- ATR
- Stock Information
- Founded
- JAZZ 2003
- ATR 1992
- Country
- JAZZ Ireland
- ATR United States
- Employees
- JAZZ N/A
- ATR N/A
- Industry
- JAZZ Biotechnology: Pharmaceutical Preparations
- ATR Plastic Products
- Sector
- JAZZ Health Care
- ATR Industrials
- Exchange
- JAZZ Nasdaq
- ATR Nasdaq
- Market Cap
- JAZZ 8.2B
- ATR 9.3B
- IPO Year
- JAZZ 2007
- ATR 1993
- Fundamental
- Price
- JAZZ $138.54
- ATR $130.37
- Analyst Decision
- JAZZ Strong Buy
- ATR Buy
- Analyst Count
- JAZZ 14
- ATR 4
- Target Price
- JAZZ $180.14
- ATR $176.00
- AVG Volume (30 Days)
- JAZZ 670.8K
- ATR 367.0K
- Earning Date
- JAZZ 11-05-2025
- ATR 10-30-2025
- Dividend Yield
- JAZZ N/A
- ATR 1.38%
- EPS Growth
- JAZZ N/A
- ATR 21.86
- EPS
- JAZZ N/A
- ATR 5.79
- Revenue
- JAZZ $4,086,695,000.00
- ATR $3,610,693,000.00
- Revenue This Year
- JAZZ $5.70
- ATR $4.27
- Revenue Next Year
- JAZZ $6.16
- ATR $4.84
- P/E Ratio
- JAZZ N/A
- ATR $22.47
- Revenue Growth
- JAZZ 4.52
- ATR 1.51
- 52 Week Low
- JAZZ $95.49
- ATR $127.85
- 52 Week High
- JAZZ $148.06
- ATR $178.03
- Technical
- Relative Strength Index (RSI)
- JAZZ 62.66
- ATR 41.85
- Support Level
- JAZZ $134.09
- ATR $128.02
- Resistance Level
- JAZZ $139.75
- ATR $132.11
- Average True Range (ATR)
- JAZZ 3.08
- ATR 2.08
- MACD
- JAZZ -0.21
- ATR 0.30
- Stochastic Oscillator
- JAZZ 83.51
- ATR 47.01
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About ATR AptarGroup Inc.
Headquartered in Crystal Lake, Illinois, AptarGroup is a leading global supplier of dispensing systems such as aerosol valves, pumps, closures, and elastomer packaging components to the consumer goods and pharmaceutical markets. With the bulk of its annual net sales coming from Europe (49% of sales) and the United States (32%), Aptar aims to increase its presence in Asia (11%) and Latin America (8%). It operates three business segments, Pharma, Beauty, and Closures. Pharma generates over two thirds of group profits.